The Swiss company plans to use proceeds from the IPO to continue development of its lead product, the anti-Abeta antibody crenezumab, which is being researched as a passive immunization treatment for Alzheimer's disease. Crenezumab, which is currently in Phase III clinical trials, is partnered with Roche company, Genentech Inc.
A US Securities and Exchange Commission filing from AC Immune did not disclose how many shares it plans to sell...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
